Tim Robinson

Cons Senior Lecturer Med Onc UoB. Breast oncology, TNBC, genetics, biomarkers. Quality of life!

[Tim Robinson @drtimrobinson]

@oncology_bg ‘No new safety signals’

[Tim Robinson @drtimrobinson]

@drsarahsam @AbiSivaMD No!

[Tim Robinson @drtimrobinson]

@teamoncology @JavierCortesMD @antoniollombar1 @BianchiniGP Indeed, remind me to not ask @BianchiniGP to examine any of my PhD students 🤯

[Gil Morgan, MD @weoncologists]

FREE EVENT IN SAN ANTONIO TODAY
MEDiscussion during #SABCS25
DEC 10, 2025 FREE REGISTRATION

⭐️REGISTER HERE👉https://t.co/YtKpzHMkZF

A Great opportunity to interact with an amazing faculty
@JavierCortesMD
@teamoncology
@antoniollombar1
@BianchiniGP
@drtimrobinson

[OncoAlert @OncoAlert]

MEDiscussion at #SABCS25 🚨Join top global experts for a high-level exchange on the latest in HER2+, HR+/luminal disease, and ctDNA. 👉 https://t.co/a1zdj0Ul13
FREE REGISTRATION

🎙 Chairs: Dr. Javier Cortés, Dr. Antonio Llombart, Dr. Naoto Ueno
🗣 Moderator: Dr. Giampaolo Bianchini
💬 Discussants: Dr. Pérez-García, Dr. Bartsch, Dr. Robinson
Don’t miss this dynamic, multi-expert dialogue shaping the future of breast cancer care.

@JavierCortesMD
@teamoncology
@antoniollombar1
@BianchiniGP
@drtimrobinson
@wearemedsir

[Tim Robinson @drtimrobinson]

@ErikaHamilton9 A lot of abstracts but not a lot of payloads!

[Tim Robinson @drtimrobinson]

This is reassuring data. We must get better at managing HFS though!

[Erika Hamilton, MD, FASCO @ErikaHamilton9]

Practice affirming. Adjuvant capecitabine for residual disease after adjuvant chemo improves outcomes.

Reassuring this is true in a real world data set and not just the CREATE-X trial. Interestingly only half receive adjuvant therapy.

#bcsm #TNBC

https://t.co/ZpFC7WN8FL

[Tim Robinson @drtimrobinson]

@JiaJennyLiu @oncocook @JCO_ASCO @Starpharma_ASX @ECMC_UK @NECTANSW Please do, I know the team at the Christie well!

[Tim Robinson @drtimrobinson]

Really important topic, please share!

@BreastCancerNow @Liz_ORiordan @Make2ndsCount

[Iain Macpherson @IR_Macpherson]

Share your experience of secondary breast cancer and sleep | Breast Cancer Now https://t.co/GyvPwcXAb0

[Tim Robinson @drtimrobinson]

@JAMouabbi @Sonyareid07 Agreed, I saw this and found it sobering. We must do better

[Tim Robinson @drtimrobinson]

@BreastDocUK Reassuring data for those on aromatase
Inhibitors

[Make 2nds Count @Make2ndsCount]

Insomnia has a huge impact on physical & mental health & even more so if you are living with secondary breast cancer. On #WorldSleepDay we're asking patients to complete our research project survey with @UniStrathclyde in tailored insomnia interventions: https://t.co/8RIg60ZakU

[Tim Robinson @drtimrobinson]

@stolaney1 @antgiorda @RebeccaDSing @SABCSSanAntonio @DFCI_BreastOnc @OncoAlert A lot of interesting questions remain…

[Tim Robinson @drtimrobinson]

@PTarantinoMD Nice data paolo. Are you able to tell us what the median pfs on tdxd was as first ADC?

[Tim Robinson @drtimrobinson]

@MelissaFrizzie1 @MGMcNamara @ncukcharity @UKINETS @TheChristieNHS @MCRCnews @CRUK_MI @FlorentMouliere @cruk_nbc Congrats!

[Tim Robinson @drtimrobinson]

@gusviani Excellent thread

[Tim Robinson @drtimrobinson]

@oncology_bg @SuyogCancer @darioT_ @DrMarkLythgoe @Nature @BreastDocUK @BreastCancerNow @ElisaAgostinett @SullivanProf We also shouldn’t forget in this context fulvestrant injections are not without therapeutic burden. Most patients hate them!

[Tim Robinson @drtimrobinson]

@saadvikdr @OncoAlert @dr_yakupergun @SuyogCancer Really really needs stratifying by pCR status: delta was 0.4% with a pathCR but toxicity I’m sure was experience by all. Trial design doesn’t allow us to unpick this. We need better trial designs!

We published on this topic recently

https://t.co/DYeoboh6vg